Trial reportBreast (Edinburgh, Scotland)2020
"Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia".
Trial report in Breast (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05213936 (Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color: A Clinical and Mechanistic Study
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Comparative efficacy of interventions for preventing chemotherapy-induced alopecia: a systematic review and network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- [Scalp cooling for the prevention of chemotherapy-induced alopecia: systematic review and meta-analysis.]Revista espanola de salud publica · 2023Pooled it
- The scalp cooling therapy for hair loss in breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Efficacy of scalp cooling to prevent chemotherapy-induced alopecia in children with acute lymphoblastic leukemia: A non-randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Effectiveness of increasing the scalp cooling duration to prevent alopecia during adjuvant chemotherapy for breast cancer: a randomized pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Trial
- Electric hand warmer versus observation to avoid discomfort during scalp cooling for chemotherapy-induced alopecia prevention: a randomized study.Scientific reports · 2023Trial
- Digital Innovation in Oncological Primary Treatment for Well-Being of Patients: Psychological Caring as Prompt for Enhancing Quality of Life.Current oncology (Toronto, Ont.) · 2021Trial
- Economic evaluation of automated scalp cooling systems for breast cancer patients in Spain.Health economics review · 2026Article
- Scalp cooling therapy in chemotherapy-induced alopecia: addressing variability in cooling duration and efficacy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines · 2025Review
- Shorter post-infusion cooling times at least as effective as longer cooling times - An observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Feasibility of anticancer treatment using scalp cooling for patients with gynecological cancer in Japan: A case series study.The journal of obstetrics and gynaecology research · 2025Article
- Prevention of chemotherapy drug-mediated human hair follicle damage: combined use of cooling with antioxidant suppresses oxidative stress and prevents matrix keratinocyte cytotoxicity.Frontiers in pharmacology · 2025Article
- Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy.The oncologist · 2024Article
- Therapeutic Effect of Superficial Scalp Hypothermia on Chemotherapy-Induced Alopecia in Breast Cancer Survivors.Journal of clinical medicine · 2024Review
- Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia.Journal of market access & health policy · 2024Article
- Efficacy of cooling therapy and α-lipoic acid derivative against chemotherapy-induced alopecia in an animal model.Cancer science · 2023Article
- Low temperature upregulating HSP70 expression to mitigate the paclitaxel-induced damages in NHEK cell.PeerJ · 2023Article
- PRO Hair Safe Study: The Patient's Perspective on the Effects of Scalp Cooling on Hair Preservation.Breast cancer (Dove Medical Press) · 2023Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized controlled trials (RCT) of scalp cooling (SC) to prevent chemotherapy induced alopecia (CIA) did not evaluate its effect on hair regrowth (HR) and was conducted in a predominantly taxane (T) treated population. We conducted an RCT of SC in a setting of anthracycline (A) and taxane chemotherapy (CT) and assessed its effect on CIA and HR.
methodsNon-metastatic breast cancer women undergoing (neo) adjuvant CT were randomized to receive SC using the Paxman scalp cooling system during every cycle of CT, or no SC. The primary end point (PEP) was successful hair preservation (HP) assessed clinically and by review of photographs after CT. HR was assessed at 6 and 12 weeks.
results51 patients were randomized to SC (34) or control arm (17) in a 2:1 ratio. Twenty-five (49%) patients received A followed by T and the two arms were balanced with respect to this factor. HP rate was significantly higher in SC arm compared to control arm (56.3% vs 0%, P = 0.000004). HR was higher in SC arm compared to control at 6 weeks (89% vs 12%; P < 0.001) and 12 weeks (100% vs 59%, P = 0.0003). Loss of hair at PEP evaluation, which was a quality of life measure, was significantly lower in SC versus control arm (45% vs 82%, P = 0.016). There were no grade 3-4 cold related adverse effects.
conclusionsWomen with breast cancer receiving A or T chemotherapy receiving SC were significantly more likely to have less than 50% hair loss after CT, superior hair regrowth and improvement in patient reported outcomes, with acceptable tolerance. It merits wider usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.